Remove Disease Remove Long-Term Care Facilities Remove Treatment
article thumbnail

COVID-19 Vaccine Developers Adjust Phase 3 Trial Protocols to Allow Authorized Vaccines | 2020-12-17

The Pharma Data

Regardless of their decisions or which treatment they receive, all participants will be monitored for two years. It’s going to change everyone’s behavior otherwise,” suggested Hayley Gans, a pediatrics and infectious diseases expert at Stanford University Medical Center.

Vaccine 52
article thumbnail

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

The Pharma Data

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. .–( BUSINESS WIRE )– Moderna, Inc., AUTHORIZED USE.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

The Pharma Data

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. Lilly subsequently developed bamlanivimab and etesevimab for administration together, in order to meet the potential challenge of SARS-CoV-2 variants likely to resist treatment with either monoclonal antibody used alone.

article thumbnail

Lilly Announces Agreement with U.S. government to Supply 300,000 vials of Investigational Neutralizing Antibody Bamlanivimab (LY-CoV555) in an Effort to Fight COVID-19

The Pharma Data

Lilly submitted a request for an EUA for bamlanivimab for the treatment of mild to moderate COVID-19 in high-risk patients to the FDA in early October. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Food and Drug Administration (FDA).

article thumbnail

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

The Pharma Data

million shots have now been administered in long-term care facilities, according to the U.S. Centers for Disease Control and Prevention. The variant is perhaps the most worrisome to public health experts, because it seems to have some ability to evade COVID-19 antibody treatments or vaccines.

Nurses 52
article thumbnail

FDA Advisory Panel Says Yes to Pfizer’s COVID Vaccine

The Pharma Data

Centers for Disease Control and Prevention will also vote on whether to recommend the vaccine and for whom, the Post reported. First in line are health care personnel and residents and staff of long-term care facilities, according to earlier recommendations released by the CDC panel.

Vaccine 52
article thumbnail

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

While COVID-19 vaccination efforts have been successful, there is still a significant need for prevention and treatment options for certain populations, including those unable to be vaccinated or those who may have an inadequate response to vaccination.”. Preliminary analyses show similar adverse events in the placebo and treatment arms.

Trials 52